We are entering into a new position today that we see a lot of potential in for the next few weeks. See the details below:

Ticker: BEAM

Name: Beam Therapeutics

Entry Price Range: under $26 (our entry price was $25.35)

Portfolio Allocation: 9% of our portfolio is allocated to this position

• As a reminder, we allocate our positions evenly. We currently have 11 positions so BEAM is 9%. If we add more positions, BEAM will become diluted to a smaller portion of the portfolio

Why we like it:

• Recent Earning: they recently reported a surprise upside on earnings

• Analyst Price Target: It is currently at the lowest price target for analyst with the median at $48.38 which is over 90% upside potential

• Momentum is picking up: It now represents as bullish on momentum, having recently come off a massive drawdown the last 2 months